

**Antisoma to de-list from Nasdaq Europe because of forthcoming
closure of market
Shares to remain listed on the London Stock Exchange**

26 August 2003, London, UK: Antisoma (LSE: ASM- Nasdaq Europe: ASOM), the UK-based biopharmaceutical company, today announces that it has received approval for a voluntary de-listing from the Nasdaq Europe Market. The de-listing of Antisoma shares will be effective from the close of business on Wednesday 10 September 2003. The decision to de-list follows the announcement by Nasdaq Europe of its intention to close by the end of November 2003.

Following the de-listing, all Antisoma shares will continue to be traded on the London Stock Exchange, where the majority of trading takes place at present. Existing shareholders will not have to take any action to transfer their shareholdings. Importantly, they will not incur any additional costs as a result of the de-listing.

Antisoma will continue to provide its shareholders with press releases and related company information on www.antisoma.com.

Enquiries:

Antisoma plc □

Raymond Spencer, Chief Financial Officer Tel: +44 (0)20 8799 8200

Financial Dynamics

Jonathan Birt Tel: +44 (0)7884 238952

About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. The Company fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the pre-clinical and clinical development of these drug candidates. Antisoma forms partnerships with pharmaceutical companies to bring its products to market. In November 2002, Antisoma signed a ground-breaking collaboration agreement with Roche to develop and commercialise products from Antisoma's pipeline.